Leukemia
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes can affect how much patients must pay out of pocket for their medications, including certain cancer drugs. Read More ›
In an updated analysis of 134 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib monotherapy, more than 90% were still responding after 41 months of treatment. Read More ›
Patients with chronic lymphocytic leukemia or mantle-cell lymphoma who were started on acalabrutinib in the United States had high rates of comorbid hypertension and other hematologic malignancies, and about two-thirds received prior ibrutinib. Read More ›
In shared decision-making, patients communicate their preferences and values to their healthcare team when treatment decisions are made. Patients who take an active role in the process tend to be more satisfied with their quality of care. Read More ›
Oral medications are being used increasingly in cancer treatment plans and are more convenient to take compared with medications administered in the doctor’s office or hospital. Oral treatments, however, have their own set of challenges that require effective communication between the patient and the healthcare team. Read More ›
In November 2019, the FDA approved a new treatment, Calquence, for patients with relapsed or refractory CLL or SLL. Read More ›
People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team. Read More ›
Chimeric antigen receptor (CAR) T-cell therapy could soon expand into chronic lymphocytic leukemia (CLL). Early clinical trials have shown responses in patients with CLL refractory to other therapies. Predicting which patients will respond is key to advancing CAR T-cell therapy into CLL. Read More ›
Targeted therapy is at the forefront of chronic lymphocytic leukemia (CLL) treatment. In many cases, targeted agents offer superior outcomes to chemotherapy, with more manageable side effects. Multiple targeted therapy options are available, and some choices depend on certain molecular markers. Read More ›
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis. Read More ›